The DOI matches its Crossref record; 251 of the 251 references it cites were found in a registry or an index.
Consensus Statement By The American Association Of Clinical Endocrinologists And American College Of Endocrinology On The Comprehensive Type 2 Diabetes Management Algorithm – 2016 EXECUTIVE SUMMARY
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 2×
“Whether achieved through lifestyle therapy, pharmacotherapy, surgery, or some combination thereof, weight loss reduces insulin resistance and can effectively prevent progression to diabetes as well as improve plasma lipid profile and BP (44,48,49,51,53,60,63).”
BackgroundEmpagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.10.018 · Cited by 8,530
James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler, J., Lackland, D. T., LeFevre, M. L., MacKenzie, T. D., Ogedegbe, O., et al. (2014) · JAMA · doi:10.1001/jama.2013.284427 · Cited by 7,950
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
Sacks, F. M., Svetkey, L. P., Vollmer, W. M., Appel, L. J., Bray, G. A., Harsha, D., Obarzanek, E., Conlin, P. R., Miller, E. R., Simons-Morton, D. G., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200101043440101 · Cited by 5,638
Tarver, T. (2014) · Journal of Consumer Health On the Internet · doi:10.1080/15398285.2014.902284 · Cited by 5,605
Dahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08089-3 · Cited by 5,407
Heart Disease and Stroke Statistics—2013 Update: A Report From the American Heart Association
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., Fox, C. S., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31828124ad · Cited by 5,292 · cited 1×
“Lipids Compared to those without diabetes, patients with T2D have a significantly increased risk of ASCVD (171).”
BackgroundGlucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
The Prevalence of Comorbid Depression in Adults With Diabetes
Anderson, R. J., Freedland, K. E., Clouse, R. E., & Lustman, P. J. (2001) · Diabetes Care · doi:10.2337/diacare.24.6.1069 · Cited by 3,926
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881 · cited 1×
“As monotherapy, fibrates have demonstrated significantly favorable outcomes in populations with high non-HDL-C (202) and low HDL-C (203).”
BackgroundColhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
(2013) · Kidney International Supplements · doi:10.1038/kisup.2012.73 · Cited by 3,206
Diabetes Prevention Program Research Group (2009) · The Lancet · doi:10.1016/s0140-6736(09)61457-4 · Cited by 3,020
DeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
Self-citationGlycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Yusuf, S., Hawken, S., Ôunpuu, S., Bautista, L., Franzosi, M. G., Commerford, P., Lang, C. C., Rumboldt, Z., Onen, C. L., Lisheng, L., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67663-5 · Cited by 2,903 · cited 1×
“The presence and severity of complications, regardless of patient BMI, should guide treatment planning and evaluation (41,42).”
BackgroundEffects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837 · cited 2×
“The addition of fenofibrate to statins in the ACCORD study showed no benefit in the overall cohort in which mean baseline triglycerides and HDL-C were within normal limits (204).”
BackgroundA Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Heart disease and stroke statistics--2013 update: a report from the American Heart Association.
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Blaha, M. J., Dai, S., Ford, E. S., Fox, C. S., Franco, S., et al. (2013) · eScholarship (California Digital Library) · Cited by 2,601
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577
Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial
Chiasson, J.-L., Josse, R. G., Gomis, R., Hanefeld, M., Karasik, A., & Laakso, M. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08905-5 · Cited by 2,543
Yokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Saito, Y., Ishikawa, Y., Oikawa, S., Sasaki, J., Hishida, H., Itakura, H., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60527-3 · Cited by 2,516
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296
Cappuccio, F. P., Cooper, D., D'Elia, L., Strazzullo, P., & Miller, M. A. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr007 · Cited by 2,146
(2000) · PubMed · Cited by 2,095
Collaborators, C. T. T. (. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60104-x · Cited by 2,081
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients
Jamerson, K., Weber, M. A., Bakris, G. L., Dahlöf, B., Pitt, B., Shi, V., Hester, A., Gupte, J., Gatlin, M., & Velazquez, E. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806182 · Cited by 2,065
XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study
Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.155 · Cited by 1,915
Pescatello, L. S., Franklin, B. A., Fagard, R., Farquhar, W. B., Kelley, G. A., & Ray, C. A. (2004) · Medicine & Science in Sports & Exercise · doi:10.1249/01.mss.0000115224.88514.3a · Cited by 1,872
Low-Density Lipoprotein Subclass Patterns and Risk of Myocardial Infarction
Austin, M. A. (1988) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1988.03410130125037 · Cited by 1,780
Bailey, C. J., & Turner, R. C. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602293340906 · Cited by 1,726
Effects of extended-release niacin with laropiprant in high-risk patients
The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668 · cited 1×
“on Global Health Outcomes [AIM-HIGH] and Heart Protection Study 2—Treatment of HDL to Reduce the Incidence of Vascular Events [HPS2-THRIVE]) failed to show CVD protection during the 3- and 4-year trial periods, respectively (212,213); by design, betweengroup differences in LDL-C were nominal at 5 mg/ dL and 10 mg/dL,…”
Mechanick, J. I., Youdim, A., Jones, D. B., Garvey, W. T., Hurley, D. L., McMahon, M. M., Heinberg, L. J., Kushner, R., Adams, T. D., Shikora, S., et al. (2013) · Obesity · doi:10.1002/oby.20461 · Cited by 1,650
Self-citationChiasson, J.-L., Josse, R. G., Gomis, R., Hanefeld, M., Karasik, A., Laakso, M., & for The STOP-NIDDM Trial Research Group (2003) · JAMA · doi:10.1001/jama.290.4.486 · Cited by 1,624
Reduction in Weight and Cardiovascular Disease Risk Factors in Individuals With Type 2 Diabetes
The Look AHEAD Research Group (2007) · Diabetes Care · doi:10.2337/dc07-0048 · Cited by 1,522
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Sabatine, M. S., Giugliano, R. P., Wiviott, S. D., Raal, F. J., Blom, D. J., Robinson, J., Ballantyne, C. M., Somaratne, R., Legg, J., Wasserman, S. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500858 · Cited by 1,509
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Severe hypoglycemia and risks of vascular events and death
Zoungas, S., Patel, A., Chalmers, J., de Galan, B. E., Li, Q., Billot, L., Woodward, M., Ninomiya, T., Neal, B., MacMahon, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003795 · Cited by 1,471
Ismail-Beigi, F., Craven, T., Banerji, M. A., Basile, J., Calles, J., Cohen, R. M., Cuddihy, R., Cushman, W. C., Genuth, S., Grimm, R. H., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60576-4 · Cited by 1,428
Home, P. D., Pocock, S. J., Beck-Nielsen, H., Curtis, P. S., Gomis, R., Hanefeld, M., Jones, N. P., Komajda, M., & McMurray, J. J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60953-3 · Cited by 1,393
de Lemos, J. A., Blazing, M. A., Wiviott, S. D., Lewis, E. F., Fox, K. A. A., White, H. D., Rouleau, J.-L., Pedersen, T. R., Gardner, L. H., Mukherjee, R., et al. (2004) · JAMA · doi:10.1001/jama.292.11.1307 · Cited by 1,333
Manninen, V, Tenkanen, L., Koskinen, P., Huttunen, J. K., Mänttäri, M., Heinonen, O. P., & Frick, M. H. (1992) · Circulation · doi:10.1161/01.cir.85.1.37 · Cited by 1,329
Cardiorenal end points in a trial of aliskiren for type 2 diabetes
Parving, H.-H., Brenner, B. M., McMurray, J. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Persson, F., Desai, A. S., Nicolaides, M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208799 · Cited by 1,319
Effects of medical therapies on retinopathy progression in type 2 diabetes
The ACCORD Study Group and ACCORD Eye Study Group (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001288 · Cited by 1,311
Bruckert, E., Hayem, G., Dejager, S., Yau, C., & Bégaud, B. (2005) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-005-5686-z · Cited by 1,226
Combined angiotensin inhibition for the treatment of diabetic nephropathy
Fried, L. F., Emanuele, N., Zhang, J. H., Brophy, M., Conner, T. A., Duckworth, W., Leehey, D. J., McCullough, P. A., O'Connor, T., Palevsky, P. M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303154 · Cited by 1,169
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
A Prospective Study of Sleep Duration and Coronary Heart Disease in Women
Ayas, N. T., White, D. P., Manson, J. E., Stampfer, M. J., Speizer, F. E., Malhotra, A., & Hu, F. B. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.2.205 · Cited by 1,155
Nutrition therapy recommendations for the management of adults with diabetes
Evert, A. B., Boucher, J. L., Cypress, M., Dunbar, S. A., Franz, M. J., Mayer-Davis, E. J., Neumiller, J. J., Nwankwo, R., Verdi, C. L., Urbanski, P., et al. (2013) · Diabetes Care · doi:10.2337/dc13-2042 · Cited by 1,129
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
Kernan, W. N., Viscoli, C. M., Furie, K. L., Young, L. H., Inzucchi, S. E., Gorman, M., Guarino, P. D., Lovejoy, A. M., Peduzzi, P. N., Conwit, R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1506930 · Cited by 1,124
A meta-analysis of alcohol consumption and the risk of 15 diseases
Corrao, G. (2004) · Preventive Medicine · doi:10.1016/j.ypmed.2003.11.027 · Cited by 1,077
Gadde, K. M., Allison, D. B., Ryan, D. H., Peterson, C. A., Troupin, B., Schwiers, M. L., & Day, W. W. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60205-5 · Cited by 1,064
Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus
Buse, J. B., Ginsberg, H. N., Bakris, G. L., Clark, N. G., Costa, F., Eckel, R., Fonseca, V., Gerstein, H. C., Grundy, S., Nesto, R. W., et al. (2007) · Diabetes Care · doi:10.2337/dc07-9917 · Cited by 1,055
Self-citationGreenway, F. L., Fujioka, K., Plodkowski, R. A., Mudaliar, S., Guttadauria, M., Erickson, J., Kim, D. D., & Dunayevich, E. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60888-4 · Cited by 1,036
Long-term effects of intensive glucose lowering on cardiovascular outcomes
The ACCORD Study Group (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1006524 · Cited by 1,035
Effects of Oral Potassium on Blood Pressure: Meta-analysis of Randomized Controlled Clinical Trials
Whelton, P. K. (1997) · JAMA · doi:10.1001/jama.1997.03540440058033 · Cited by 1,010
Association of usual sleep duration with hypertension: the Sleep Heart Health Study
Gottlieb, D. J., Redline, S., Nieto, F. J., Baldwin, C. M., Newman, A. B., Resnick, H. E., & Punjabi, N. M. (2006) · Sleep · doi:10.1093/sleep/29.8.1009 · Cited by 947
Church, T. S., Blair, S. N., Cocreham, S., Johannsen, N., Johnson, W., Kramer, K., Mikus, C. R., Myers, V., Nauta, M., Rodarte, R. Q., et al. (2010) · JAMA · doi:10.1001/jama.2010.1710 · Cited by 944
Bonds, D. E., Miller, M. E., Bergenstal, R. M., Buse, J. B., Byington, R. P., Cutler, J. A., Dudl, R. J., Ismail-Beigi, F., Kimel, A. R., Hoogwerf, B., et al. (2010) · BMJ · doi:10.1136/bmj.b4909 · Cited by 933 · cited 1×
“In ACCORD, severe hypoglycemia may have accounted for a substantial portion of excess mortality among patients receiving intensive therapy, although the hazard ratio for hypoglycemia-associated deaths was higher in the standard treatment group (80).”
Backgroundn–3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203859 · Cited by 929
Multicenter, placebo-controlled trial of lorcaserin for weight management.
Smith, S. R., Weissman, N. J., Anderson, C. M., Sanchez, M., Chuang, E., Stubbe, S., Bays, H., & Shanahan, W. R. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909809 · Cited by 911
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
Salpeter, S. R., Greyber, E., Pasternak, G. A., & Salpeter (posthumous), E. E. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002967.pub4 · Cited by 893
Peters, A. L., Buschur, E. O., Buse, J. B., Cohan, P., Diner, J. C., & Hirsch, I. B. (2015) · Diabetes Care · doi:10.2337/dc15-0843 · Cited by 849
Self-citationon behalf of the NN8022-1923 Investigators, Wadden, T. A., Hollander, P., Klein, S., Niswender, K., Woo, V, Hale, P. M., & Aronne, L. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.120 · Cited by 842
on behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia · doi:10.1007/s00125-009-1472-y · Cited by 835
Risk of hypoglycaemia in types 1 and 2 diabetes: Effects of treatment modalities and their duration
UK Hypoglycaemia Study Group (2007) · Diabetologia · doi:10.1007/s00125-007-0599-y · Cited by 825
Bolen, S., Feldman, L., Vassy, J., Wilson, L., Yeh, H.-C., Marinopoulos, S., Wiley, C., Selvin, E., Wilson, R., Bass, E. B., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-6-200709180-00178 · Cited by 823
KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
Authors, N. (2024) · KIDNEYS · doi:10.22141/2307-1257.13.2.2024.456 · Cited by 821
Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy
Cannon, C. P., Steinberg, B. A., Murphy, S. A., Mega, J. L., & Braunwald, E. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.04.070 · Cited by 770
Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance
DeFronzo, R. A., Tripathy, D., Schwenke, D. C., Banerji, M., Bray, G. A., Buchanan, T. A., Clement, S. C., Henry, R. R., Hodis, H. N., Kitabchi, A. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010949 · Cited by 766 · cited 1×
“In clinical trials, thiazolidinediones (TZDs) prevented future development of diabetes in 60 to 75% of subjects with prediabetes, but this class of drugs has been associated with a number of adverse outcomes (67-69).”
BackgroundSelf-citationon behalf of the NN8022-1807 Investigators, Astrup, A., Carraro, R., Finer, N., Harper, A., Kunesova, M., Lean, M. E. J., Niskanen, L., Rasmussen, M. F., Rissanen, A., et al. (2012) · International Journal of Obesity · doi:10.1038/ijo.2011.158 · Cited by 757
Zannad, F., Cannon, C. P., Cushman, W. C., Bakris, G. L., Menon, V., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., Wilson, C., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62225-x · Cited by 757
Scirica, B. M., Braunwald, E., Raz, I., Cavender, M. A., Morrow, D. A., Jarolim, P., Udell, J. A., Mosenzon, O., Im, K., Umez-Eronini, A. A., et al. (2014) · Circulation · doi:10.1161/circulationaha.114.010389 · Cited by 725
A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
Blom, D. J., Hala, T., Bolognese, M., Lillestol, M. J., Toth, P. D., Burgess, L., Ceska, R., Roth, E., Koren, M. J., Ballantyne, C. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1316222 · Cited by 720
Apovian, C. M., Aronne, L., Rubino, D., Still, C., Wyatt, H., Burns, C., Kim, D., Dunayevich, E., & for the COR‐II Study Group (2013) · Obesity · doi:10.1002/oby.20309 · Cited by 720
Garvey, W. T., Ryan, D. H., Look, M., Gadde, K. M., Allison, D. B., Peterson, C. A., Schwiers, M., Day, W. W., & Bowden, C. H. (2012) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.024927 · Cited by 716
Self-citationAllison, D. B., Gadde, K. M., Garvey, W. T., Peterson, C. A., Schwiers, M. L., Najarian, T., Tam, P. Y., Troupin, B., & Day, W. W. (2012) · Obesity · doi:10.1038/oby.2011.330 · Cited by 711
Self-citationFollow-up of glycemic control and cardiovascular outcomes in type 2 diabetes
Hayward, R. A., Reaven, P. D., Wiitala, W. L., Bahn, G. D., Reda, D. J., Ge, L., McCarren, M., Duckworth, W. C., & Emanuele, N. V. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414266 · Cited by 668 · cited 1×
“6 fewer cardiovascular events per 1,000 personyears), whereas mortality risk remained the same between treatment groups (78).”
BackgroundHirsch, I. B. (2005) · New England Journal of Medicine · doi:10.1056/nejmra040832 · Cited by 667
Self-citationColberg (2010) · doi:10.2337/dc10-1548 · Cited by 656
Hanefeld, M. (2004) · European Heart Journal · doi:10.1016/s0195-668x(03)00468-8 · Cited by 641
Hegele, R. A., Ginsberg, H. N., Chapman, M. J., Nordestgaard, B. G., Kuivenhoven, J. A., Averna, M., Borén, J., Bruckert, E., Catapano, A. L., Descamps, O. S., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70191-8 · Cited by 635
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 629
Self-citationHermansen, K., Davies, M., Derezinski, T., Martinez Ravn, G., Clauson, P., Home, P., & on behalf of the Levemir Treat-to-Target Study Group (2006) · Diabetes Care · doi:10.2337/dc05-1365 · Cited by 627
Association between Reduced Sleep and Weight Gain in Women
Patel, S. R., Malhotra, A., White, D. P., Gottlieb, D. J., & Hu, F. B. (2006) · American Journal of Epidemiology · doi:10.1093/aje/kwj280 · Cited by 617
ACSM's resource manual for Guidelines for exercise testing and prescription
Kaminsky, L. A. (2006) · Acquire (CQUniversity) · Cited by 605
Effects of Diet and Sodium Intake on Blood Pressure: Subgroup Analysis of the DASH-Sodium Trial
Vollmer, W. M., Sacks, F. M., Ard, J., Appel, L. J., Bray, G. A., Simons-Morton, D. G., Conlin, P. R., Svetkey, L. P., Erlinger, T. P., Moore, T. J., et al. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-12-200112180-00005 · Cited by 598
Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events
Boekholdt, S. M., Hovingh, G. K., Mora, S., Arsenault, B. J., Amarenco, P., Pedersen, T. R., LaRosa, J. C., Waters, D. D., DeMicco, D. A., Simes, R. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.02.615 · Cited by 581
Nicotinic acid: the broad‐spectrum lipid drug. A 50th anniversary review
CARLSON, L. A. (2005) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2005.01528.x · Cited by 581
Efficacy and safety of degludec versus glargine in type 2 diabetes.
Marso, S. P., McGuire, D. K., Zinman, B., Poulter, N. R., Emerson, S. S., Pieber, T. R., Pratley, R. E., Haahr, P.-M., Lange, M., Brown-Frandsen, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615692 · Cited by 574
The Diabetes Prevention Program Research Group (2005) · Diabetes Care · doi:10.2337/diacare.28.4.888 · Cited by 572
Fidler, M. C., Sanchez, M., Raether, B., Weissman, N. J., Smith, S. R., Shanahan, W. R., & Anderson, C. M. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1256 · Cited by 561
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.glsuppl · Cited by 559
Self-citationWadden, T. A., Foreyt, J. P., Foster, G. D., Hill, J. O., Klein, S., O'Neil, P. M., Perri, M. G., Pi‐Sunyer, F. X., Rock, C. L., Erickson, J. S., et al. (2011) · Obesity · doi:10.1038/oby.2010.147 · Cited by 558
Wright, A., Burden, A. C. F., Paisey, R. B., Cull, C. A., Holman, R. R., & for the U.K. Prospective Diabetes Study Group (2002) · Diabetes Care · doi:10.2337/diacare.25.2.330 · Cited by 556
Scott, R., O'Brien, R., Fulcher, G., Pardy, C., d'Emden, M., Tse, D., Taskinen, M.-R., Ehnholm, C., Keech, A., & on behalf of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-1543 · Cited by 551
Knopp, R. H., d’Emden, M., Smilde, J. G., Pocock, S. J., & on behalf of the ASPEN Study Group (2006) · Diabetes Care · doi:10.2337/dc05-2415 · Cited by 550
Pop-Busui, R., Evans, G. W., Gerstein, H. C., Fonseca, V., Fleg, J. L., Hoogwerf, B. J., Genuth, S., Grimm, R. H., Corson, M. A., Prineas, R., et al. (2010) · Diabetes Care · doi:10.2337/dc10-0125 · Cited by 540 · cited 1×
“Cardiovascular autonomic neuropathy may be another useful predictor of cardiovascular risk, and a combination of cardiovascular autonomic neuropathy (81) and symptoms of peripheral neuropathy increase the odds ratio to 4.”
BackgroundSelf-citationRosiglitazone-Associated Fractures in Type 2 Diabetes
Kahn, S. E., Zinman, B., Lachin, J. M., Haffner, S. M., Herman, W. H., Holman, R. R., Kravitz, B. G., Yu, D., Heise, M. A., Aftring, R. P., et al. (2008) · Diabetes Care · doi:10.2337/dc07-2270 · Cited by 537
Azadbakht, L., Mirmiran, P., Esmaillzadeh, A., Azizi, T., & Azizi, F. (2005) · Diabetes Care · doi:10.2337/diacare.28.12.2823 · Cited by 536
Jellinger, P. S., Smith, D. A., Mehta, A. E., Ganda, O., Handelsman, Y., Rodbard, H. W., Shepherd, M. D., & Seibel, J. A. (2012) · Endocrine Practice · doi:10.4158/ep.18.s1.1 · Cited by 533
Self-citationO'Neil, P. M., Smith, S. R., Weissman, N. J., Fidler, M. C., Sanchez, M., Zhang, J., Raether, B., Anderson, C. M., & Shanahan, W. R. (2012) · Obesity · doi:10.1038/oby.2012.66 · Cited by 530
One-year weight losses in the Look AHEAD study: factors associated with success
Wadden, T. A., West, D. S., Neiberg, R. H., Wing, R. R., Ryan, D. H., Johnson, K. C., Foreyt, J. P., Hill, J. O., Trence, D. L., Vitolins, M. Z., et al. (2009) · Obesity · doi:10.1038/oby.2008.637 · Cited by 525
Shepherd, J., Barter, P., Carmena, R., Deedwania, P., Fruchart, J.-C., Haffner, S., Hsia, J., Breazna, A., LaRosa, J., Grundy, S., et al. (2006) · Diabetes Care · doi:10.2337/dc05-2465 · Cited by 525
Dipeptidyl peptidase‐4 inhibitors in the treatment of type 2 diabetes: a comparative review
Deacon, C. F. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01306.x · Cited by 525
Phung, O. J. (2010) · JAMA · doi:10.1001/jama.2010.405 · Cited by 520
n–3 Fatty Acids in Patients with Multiple Cardiovascular Risk Factors
The Risk and Prevention Study Collaborative Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205409 · Cited by 510
Buse, J. B., Bergenstal, R. M., Glass, L. C., Heilmann, C. R., Lewis, M. S., Kwan, A. Y. M., Hoogwerf, B. J., & Rosenstock, J. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-2-201101180-00300 · Cited by 506
Outpatient Insulin Therapy in Type 1 and Type 2 Diabetes Mellitus: Scientific Review
DeWitt, D. E., & Hirsch, I. B. (2003) · JAMA · doi:10.1001/jama.289.17.2254 · Cited by 502
Self-citationHollander, P., Gupta, A. K., Plodkowski, R., Greenway, F., Bays, H., Burns, C., Klassen, P., Fujioka, K., & for the COR-Diabetes Study Group (2013) · Diabetes Care · doi:10.2337/dc13-0234 · Cited by 501
Thiazolidinedione Use and Bone Loss in Older Diabetic Adults
Schwartz, A. V., Sellmeyer, D. E., Vittinghoff, E., Palermo, L., Lecka-Czernik, B., Feingold, K. R., Strotmeyer, E. S., Resnick, H. E., Carbone, L., Beamer, B. A., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2226 · Cited by 500
Chaput, J., Després, J., Bouchard, C., & Tremblay, A. (2007) · Obesity · doi:10.1038/oby.2007.512 · Cited by 498
Prevention of Type 2 Diabetes With Troglitazone in the Diabetes Prevention Program
The Diabetes Prevention Program Research Group* (2005) · Diabetes · doi:10.2337/diabetes.54.4.1150 · Cited by 474
Wilding, J. P. H., Woo, V., Soler, N. G., Pahor, A., Sugg, J., Rohwedder, K., Parikh, S., & for the Dapagliflozin 006 Study Group* (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-6-201203200-00003 · Cited by 467
Bangalore, S., Kumar, S., Lobach, I., & Messerli, F. H. (2011) · Circulation · doi:10.1161/circulationaha.110.016337 · Cited by 437
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
Salpeter, S. R., Greyber, E., Pasternak, G. A., & Salpeter (posthumous), E. E. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002967.pub3 · Cited by 434
Use of Metformin in the Setting of Mild-to-Moderate Renal Insufficiency
Lipska, K. J., Bailey, C. J., & Inzucchi, S. E. (2011) · Diabetes Care · doi:10.2337/dc10-2361 · Cited by 432
Janka, H. U., Plewe, G., Riddle, M. C., Kliebe-Frisch, C., Schweitzer, M. A., & Yki-Järvinen, H. (2005) · Diabetes Care · doi:10.2337/diacare.28.2.254 · Cited by 414
Kip, K. E., Marroquin, O. C., Kelley, D. E., Johnson, B. D., Kelsey, S. F., Shaw, L. J., Rogers, W. J., & Reis, S. E. (2004) · Circulation · doi:10.1161/01.cir.0000115514.44135.a8 · Cited by 412
Riddle, M. C., Ambrosius, W. T., Brillon, D. J., Buse, J. B., Byington, R. P., Cohen, R. M., Goff, D. C., Malozowski, S., Margolis, K. L., Probstfield, J. L., et al. (2010) · Diabetes Care · doi:10.2337/dc09-1278 · Cited by 406
Mechanick, J. I., Youdim, A., Jones, D. B., Garvey, W. T., Hurley, D. L., McMahon, M. M., Heinberg, L. J., Kushner, R., Adams, T. D., Shikora, S., et al. (2013) · Endocrine Practice · doi:10.4158/ep12437.gl · Cited by 395
Self-citationReduced Hypoglycemia Risk With Insulin Glargine
Rosenstock, J., Dailey, G., Massi-Benedetti, M., Fritsche, A., Lin, Z., & Salzman, A. (2005) · Diabetes Care · doi:10.2337/diacare.28.4.950 · Cited by 371
Rosenstock, J., Jelaska, A., Frappin, G., Salsali, A., Kim, G., Woerle, H. J., & Broedl, U. C. (2014) · Diabetes Care · doi:10.2337/dc13-3055 · Cited by 363
Handelsman, Y., Henry, R. R., Bloomgarden, Z. T., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Ferrannini, E., Fonseca, V. A., Garber, A. J., Grunberger, G., et al. (2016) · Endocrine Practice · doi:10.4158/ep161292.ps · Cited by 358
Self-citationSleight, P., Redon, J., Verdecchia, P., Mancia, G., Gao, P., Fagard, R., Schumacher, H., Weber, M., Böhm, M., Williams, B., et al. (2009) · Journal of Hypertension · doi:10.1097/hjh.0b013e32832d7370 · Cited by 352
Update on developments with SGLT2 inhibitors in the management of type 2 diabetes
Nauck, M. (2014) · Drug Design, Development and Therapy · doi:10.2147/dddt.s50773 · Cited by 343
Rahman, M. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.8.936 · Cited by 340
Balducci, S. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.380 · Cited by 329
Anxiety and Poor Glycemic Control: A Meta-Analytic Review of the Literature
Anderson, R. J., Grigsby, A. B., Freedland, K. E., De Groot, M., McGill, J. B., Clouse, R. E., & Lustman, P. J. (2002) · The International Journal of Psychiatry in Medicine · doi:10.2190/klgd-4h8d-4ryl-twq8 · Cited by 328
Self-citationRole of Snoring and Daytime Sleepiness in Occupational Accidents
LINDBERG, E., CARTER, N., GISLASON, T., & JANSON, C. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.11.2102028 · Cited by 326
Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus
Yki-Järvinen, H., Kauppila, M., Kujansuu, E., Lahti, J., Marjanen, T., Niskanen, L., Rajala, S., Ryysy, L., Salo, S., Seppälä, P., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199211123272005 · Cited by 324 · cited 1×
“Premixed insulins provide less dosing flexibility and have been associated with a higher frequency of hypoglycemic events compared to basal and basal-bolus regimens (128-130).”
BackgroundPioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes
Lewis, J. D., Habel, L. A., Quesenberry, C. P., Strom, B. L., Peng, T., Hedderson, M. M., Ehrlich, S. F., Mamtani, R., Bilker, W., Vaughn, D. J., et al. (2015) · JAMA · doi:10.1001/jama.2015.7996 · Cited by 320
Saito, Y., Yokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Ishikawa, Y., Oikawa, S., Sasaki, J., Hishida, H., Itakura, H., et al. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.06.003 · Cited by 316
Davidson, M. H., Dillon, M. A., Gordon, B., Jones, P., Samuels, J., Weiss, S., Isaacsohn, J., Toth, P., & Burke, S. K. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.16.1893 · Cited by 307
Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes
Vilsbøll, T., Rosenstock, J., Yki‐Järvinen, H., Cefalu, W. T., Chen, Y., Luo, E., Musser, B., Andryuk, P. J., Ling, Y., Kaufman, K. D., et al. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01173.x · Cited by 305
Effects of four maintenance programs on the long-term management of obesity
Perri, M. G., McAllister, D. A., Gange, J. J., Jordan, R. C., McAdoo, W. G., & Nezu, A. M. (1988) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.56.4.529 · Cited by 304
Metabolic and weight-loss effects of a long-term dietary intervention in obese patients
Ditschuneit, H. H., Flechtner-Mors, M., Johnson, T. D., & Adler, G. (1999) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/69.2.198 · Cited by 304
Roumie, C. L., Hung, A. M., Greevy, R. A., Grijalva, C. G., Liu, X., Murff, H. J., Elasy, T. A., & Griffin, M. R. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-9-201211060-00003 · Cited by 300
Flechtner‐Mors, M., Ditschuneit, H. H., Johnson, T. D., Suchard, M. A., & Adler, G. (2000) · Obesity Research · doi:10.1038/oby.2000.48 · Cited by 285
Wile, D. J., & Toth, C. (2010) · Diabetes Care · doi:10.2337/dc09-0606 · Cited by 283
Weighing Risks and Benefits of Liraglutide — The FDA's Review of a New Antidiabetic Therapy
Parks, M., & Rosebraugh, C. (2010) · New England Journal of Medicine · doi:10.1056/nejmp1001578 · Cited by 275
Association of Biochemical B12 Deficiency With Metformin Therapy and Vitamin B12 Supplements
Reinstatler, L., Qi, Y. P., Williamson, R. S., Garn, J. V., & Oakley, G. P. (2012) · Diabetes Care · doi:10.2337/dc11-1582 · Cited by 265
Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials
Zhang, X.-L., Zhu, Q.-Q., Zhu, L., Chen, J.-Z., Chen, Q.-H., Li, G.-N., Xie, J., Kang, L.-N., & Xu, B. (2015) · BMC Medicine · doi:10.1186/s12916-015-0358-8 · Cited by 260
Bromocriptine: A Sympatholytic, D2-Dopamine Agonist for the Treatment of Type 2 Diabetes
DeFronzo, R. A. (2011) · Diabetes Care · doi:10.2337/dc11-0064 · Cited by 257
Self-citationLiese, A. D., Nichols, M., Sun, X., D'Agostino, R. B., & Haffner, S. M. (2009) · Diabetes Care · doi:10.2337/dc09-0228 · Cited by 256
Combination lipid therapy in type 2 diabetes
(2010) · New England Journal of Medicine · doi:10.1056/nejmc1006407 · Cited by 245
SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System
Fadini, G. P., Bonora, B. M., & Avogaro, A. (2017) · Diabetologia · doi:10.1007/s00125-017-4301-8 · Cited by 242
Lee, M., Saver, J. L., Towfighi, A., Chow, J., & Ovbiagele, B. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.04.020 · Cited by 240
Garvey, W. T., Garber, A. J., Mechanick, J. I., Bray, G. A., Dagogo-Jack, S., Einhorn, D., Grunberger, G., Handelsman, Y., Hennekens, C. H., Hurley, D. L., et al. (2014) · Endocrine Practice · doi:10.4158/ep14280.ps · Cited by 238 · cited 2×
“Weight loss should be considered in all overweight and obese patients with prediabetes or T2D, given the known therapeutic effects of weight loss to lower glycemia, improve the lipid profile, reduce BP, and decrease mechanical strain on the lower extremities (hips and knees) (2,38).”
BackgroundSelf-citationGarber, A. J., Handelsman, Y., Einhorn, D., Bergman, D. A., Bloomgarden, Z. T., Fonseca, V., Garvey, W. T., Gavin, J. R., Grunberger, G., Horton, E. S., et al. (2008) · Endocrine Practice · doi:10.4158/ep.14.7.933 · Cited by 237
Self-citationRidker, P. M., Morrow, D. A., Rose, L. M., Rifai, N., Cannon, C. P., & Braunwald, E. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.02.080 · Cited by 236
Recent advances in physiological lipoprotein metabolism
Ramasamy, I. (2014) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2013-0358 · Cited by 235
Rosenstock, J., Klaff, L. J., Schwartz, S., Northrup, J., Holcombe, J. H., Wilhelm, K., & Trautmann, M. (2010) · Diabetes Care · doi:10.2337/dc09-1203 · Cited by 229
Consistency With the DASH Diet and Incidence of Heart Failure
Levitan, E. B., Wolk, A., & Mittleman, M. A. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.56 · Cited by 227
Canner, P. L., Furberg, C. D., Terrin, M. L., & McGovern, M. E. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.09.013 · Cited by 226
Bays, H., Gaudet, D., Weiss, R., Ruiz, J. L., Watts, G. F., Gouni-Berthold, I., Robinson, J., Zhao, J., Hanotin, C., & Donahue, S. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1520 · Cited by 221
Critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations
Rosak, C., & Mertes (2012) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s28340 · Cited by 216
Garvey, W. T., Ryan, D. H., Henry, R., Bohannon, N. J. V., Toplak, H., Schwiers, M., Troupin, B., & Day, W. W. (2014) · Diabetes Care · doi:10.2337/dc13-1518 · Cited by 215
Self-citationGaziano, J. M., Cincotta, A. H., O'Connor, C. M., Ezrokhi, M., Rutty, D., Ma, Z. J., & Scranton, R. E. (2010) · Diabetes Care · doi:10.2337/dc09-2009 · Cited by 213
Long-acting insulin analogues versus NPH human insulin in type 2 diabetes
Monami, M., Marchionni, N., & Mannucci, E. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.04.007 · Cited by 211
The cardiovascular safety of diabetes drugs–insights from the rosiglitazone experience
Hiatt, W. R., Kaul, S., & Smith, R. J. (2013) · New England Journal of Medicine · doi:10.1056/nejmp1309610 · Cited by 204
Metz, J. A., Stern, J. S., Kris-Etherton, P., Reusser, M. E., Morris, C. D., Hatton, D. C., Oparil, S., Haynes, R. B., Resnick, L. M., Pi-Sunyer, F. X., et al. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.14.2150 · Cited by 196
Bruckert, E., Labreuche, J., Deplanque, D., Touboul, P.-J., & Amarenco, P. (2011) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e318202709f · Cited by 192
Deacon, C. F., Mannucci, E., & Ahrén, B. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01603.x · Cited by 190
Harkness, E., Macdonald, W., Valderas, J., Coventry, P., Gask, L., & Bower, P. (2010) · Diabetes Care · doi:10.2337/dc09-1519 · Cited by 188
Hansen, D., Dendale, P., Jonkers, R. A. M., Beelen, M., Manders, R. J. F., Corluy, L., Mullens, A., Berger, J., Meeusen, R., & van Loon, L. J. C. (2009) · Diabetologia · doi:10.1007/s00125-009-1354-3 · Cited by 185
The Current State of Niacin in Cardiovascular Disease Prevention
Lavigne, P. M., & Karas, R. H. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.10.030 · Cited by 185
Adjust to Target in Type 2 Diabetes
Bergenstal, R. M., Johnson, M., Powers, M. A., Wynne, A., Vlajnic, A., Hollander, P., & Rendell, M. (2008) · Diabetes Care · doi:10.2337/dc07-2137 · Cited by 181
Low-Intensity Exercise Reduces the Prevalence of Hyperglycemia in Type 2 Diabetes
MANDERS, R. J. F., VAN DIJK, J.-W. M., & VAN LOON, L. J. C. (2010) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0b013e3181b3b16d · Cited by 180
Barnett, A. H., Charbonnel, B., Donovan, M., & Fleming, D. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.665046 · Cited by 162
Mechanick, J. I., Garber, A. J., Handelsman, Y., Garvey, W. T., Beir, D. M., Bohannon, N. J. V., Bray, G. A., Bush, M. A., Evans, J. G., Hurley, D. L., et al. (2012) · Endocrine Practice · doi:10.4158/ep12160.ps · Cited by 160
Self-citationDeVries, J. H., Bain, S. C., Rodbard, H. W., Seufert, J., D’Alessio, D., Thomsen, A. B., Zychma, M., Rosenstock, J., & on behalf of the Liraglutide-Detemir Study Group (2012) · Diabetes Care · doi:10.2337/dc11-1928 · Cited by 159
Pioglitazone and risk of bladder cancer: a meta‐analysis of controlled studies
Ferwana, M. S., Firwana, B., Hasan, R., Al-Mallah, M. H., Kim, S., Montori, V. M., & Murad, M. H. (2013) · Diabetic Medicine · doi:10.1111/dme.12144 · Cited by 153
González-Campoy, J. M., CASTORINO, K. N., Ebrahim, A., Hurley, D., Jovanovič, L., Mechanick, J. I., Petak, S. M., Yu, Y., Jeor, S. T. S., Harris, K. A., et al. (2013) · Endocrine Practice · doi:10.4158/ep13155.gl · Cited by 153
Self-citationPrevalence of sleep apnea and electrocardiographic disturbances in morbidly obese patients
Valencia‐Flores, M., Orea, A., Castaño, V. A., Resendiz, M., Rosales, M., Rebollar, V., Santiago, V., Gallegos, J., Campos, R. M., González, J., et al. (2000) · Obesity Research · doi:10.1038/oby.2000.31 · Cited by 152
Winkelman, J. W., Redline, S. S., Baldwin, C. M., Resnick, H. E., Newman, A. B., & Gottlieb, D. J. (2009) · SLEEP · doi:10.1093/sleep/32.6.772 · Cited by 152
Gough, S. C. L., Bhargava, A., Jain, R., Mersebach, H., Rasmussen, S., & Bergenstal, R. M. (2013) · Diabetes Care · doi:10.2337/dc12-2329 · Cited by 150
Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release
Garvey, W. T., Ryan, D. H., Bohannon, N. J. V., Kushner, R. F., Rueger, M., Dvorak, R. V., & Troupin, B. (2014) · Diabetes Care · doi:10.2337/dc14-0930 · Cited by 149
Self-citation
Cited by
International consensus on use of continuous glucose monitoring
Danne, T., Nimri, R., Battelino, T., Bergenstal, R. M., Close, K. L., DeVries, J. H., Garg, S., Heinemann, L., Hirsch, I., Amiel, S. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1600 · Cited by 2,069
Self-citationClinical review of antidiabetic drugs: implications for type 2 diabetes mellitus management
Chaudhury, A., Duvoor, C., Reddy Dendi, V. S., Kraleti, S., Chada, A., Ravilla, R., Marco, A., Shekhawat, N. S., Montales, M. T., Kuriakose, K., et al. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00006 · Cited by 1,500
Jellinger, P. S., Handelsman, Y., Rosenblit, P. D., Bloomgarden, Z. T., Fonseca, V. A., Garber, A. J., Grunberger, G., Guerin, C. K., Bell, D. S. H., Mechanick, J. I., et al. (2017) · Endocrine Practice · doi:10.4158/ep171764.appgl · Cited by 1,094
Self-citationMetformin: historical overview
Bailey, C. J. (2017) · Diabetologia · doi:10.1007/s00125-017-4318-z · Cited by 1,055
Eslam, M., Sarin, S. K., Wong, V. W.-S., Fan, J.-G., Kawaguchi, T., Ahn, S. H., Zheng, M.-H., Shiha, G., Yilmaz, Y., Gani, R., et al. (2020) · Hepatology International · doi:10.1007/s12072-020-10094-2 · Cited by 833
Metadata
- Authors
- Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., Garber, J. R., Garvey, W. T., Grunberger, G., Handelsman, Y., Henry, R. R., Hirsch, I. B., Jellinger, P. S., McGill, J. B., Mechanick, J. I., Rosenblit, P. D., & Umpierrez, G. E.
- Venue
- Endocrine Practice
- Publisher
- Elsevier BV
- Published
- 2016-01
- Volume
- 22
- Issue
- 1
- Pages
- 84-113
- ISSN
- 1530-891X (ISSN-L)
- OpenAlex
- W2193379135
- Cited by
- 878
- References
- 251
- FWCI
- 160.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.